Dupixent reduced COPD exacerbations and improved lung function in uncontrolled COPD patients with type 2 inflammation in the NOTUS Phase 3 trial.

Dupixent (dupilumab) reduced COPD exacerbations by 34% and improved lung function in uncontrolled COPD patients with type 2 inflammation in the NOTUS Phase 3 trial. The results, presented at the American Thoracic Society International Conference and published in the New England Journal of Medicine, support Dupixent as the first targeted therapy for COPD in over a decade.

May 20, 2024
8 Articles

Further Reading